Related Experiment Video

Updated: Mar 22, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.7K

CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies

Yaghoub Safdari1,2, Vahideh Ahmadzadeh3, Safar Farajnia4,5

  • 1Cellular and Molecular Research Center, Taleghani Children Hospital, Gorgan University of Medical Sciences, Gorgan, Iran.

Investigational New Drugs
|April 15, 2016
PubMed

Insights

New experimental agents targeting CD20-positive B-cell tumors offer improved outcomes. These novel therapies aim to overcome treatment resistance in lymphoma and leukemia, optimizing cytotoxic activity for better patient benefit.

Area of Science:

  • Immunology
  • Oncology
  • Hematology

Background:

  • CD20 antigen expression on malignant B cells is a key target for monoclonal antibody therapies.
  • Current anti-CD20 antibody treatments are effective but can be limited by emergent treatment resistance in lymphoma and leukemia.
  • Optimizing cytotoxic activity and overcoming resistance are critical goals in B-cell malignancies.

Purpose of the Study:

  • To review emerging experimental agents targeting CD20-positive B-cell tumors.
  • To highlight therapeutic strategies that enhance conventional treatments.
  • To discuss approaches for overcoming resistance to anti-CD20 therapies.

Main Methods:

  • Literature review of recent advancements in anti-CD20 therapies.
  • Analysis of novel experimental agents and combination strategies.
  • Focus on agents benefiting CD20-positive B-cell malignancies.

Main Results:

  • Several new experimental agents show promise in targeting CD20-positive B-cell tumors.
  • Combination therapies are being developed to enhance cytotoxic activity and combat resistance.
  • These novel approaches aim to improve outcomes for patients with refractory or relapsed disease.

Conclusions:

  • Novel experimental agents and combination therapies represent a significant advancement in treating CD20-positive B-cell tumors.
  • These strategies hold potential for optimizing treatment efficacy and overcoming resistance.
  • Further research is warranted to fully elucidate the benefits of these new therapeutic avenues.
Keywords:
Antibody-based therapeuticsB-cell malignanciesCD20 antigenCombination therapy

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.1K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.9K